SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

Search

Laboratorios Farmaceuticos Rovi SA

Fermé

SecteurSoins de santé

84.9 0.53

Résumé

Variation du prix de l'action

24h

Actuel

Min

83.8

Max

84.95

Chiffres clés

By Trading Economics

Revenu

49M

76M

Ventes

51M

210M

P/E

Moyenne du Secteur

32.945

108.767

BPA

1.135

Rendement du dividende

1.2

Marge bénéficiaire

35.965

Employés

2,197

EBITDA

49M

84M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+6.38% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.20%

2.21%

Prochains Résultats

7 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

742M

4B

Ouverture précédente

84.37

Clôture précédente

84.9

Sentiment de l'Actualité

By Acuity

24%

76%

55 / 352 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

27 févr. 2026, 23:53 UTC

Actions en Tendance

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 févr. 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

27 févr. 2026, 17:55 UTC

Actions en Tendance

Toronto Stocks Decline, But Remain On Track for Weekly Gains

27 févr. 2026, 23:46 UTC

Acquisitions, Fusions, Rachats

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 févr. 2026, 23:33 UTC

Acquisitions, Fusions, Rachats

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 févr. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

27 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 févr. 2026, 21:30 UTC

Résultats

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 févr. 2026, 21:30 UTC

Market Talk
Acquisitions, Fusions, Rachats

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 févr. 2026, 21:20 UTC

Acquisitions, Fusions, Rachats

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 févr. 2026, 21:17 UTC

Résultats

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 févr. 2026, 21:10 UTC

Acquisitions, Fusions, Rachats

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 févr. 2026, 21:09 UTC

Acquisitions, Fusions, Rachats

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 févr. 2026, 21:00 UTC

Résultats

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 févr. 2026, 20:31 UTC

Acquisitions, Fusions, Rachats

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 févr. 2026, 20:24 UTC

Market Talk

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 févr. 2026, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27 févr. 2026, 20:12 UTC

Market Talk

Nike Seen With Further Challenges in China -- Market Talk

27 févr. 2026, 19:44 UTC

Market Talk

Gold Caps Historic Month -- Market Talk

27 févr. 2026, 19:39 UTC

Résultats

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 févr. 2026, 19:38 UTC

Résultats

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

27 févr. 2026, 18:53 UTC

Acquisitions, Fusions, Rachats

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

27 févr. 2026, 18:45 UTC

Résultats

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

27 févr. 2026, 18:45 UTC

Market Talk

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

27 févr. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 févr. 2026, 17:07 UTC

Résultats

Pemex Cuts 4Q Loss As Operating Results Improve

27 févr. 2026, 17:00 UTC

Market Talk

Corn Rides Oil Momentum Higher -- Market Talk

27 févr. 2026, 16:31 UTC

Market Talk

Canadian Economy Shows Resilience -- Market Talk

27 févr. 2026, 16:17 UTC

Market Talk

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

27 févr. 2026, 15:49 UTC

Résultats

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

6.38% hausse

Prévisions sur 12 Mois

Moyen 90 EUR  6.38%

Haut 90 EUR

Bas 90 EUR

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

55 / 352Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat